Astaxanthin alleviates neuropathic pain by inhibiting the MAPKs and NF-κB pathways

Neuropathic pain is a complex condition that usually lasts a lifetime and has a major negative impact on life after injury. Improving pain management is an important and unmet need. Astaxanthin (AST) is a natural marine medicine with effective antioxidant and anti-inflammatory properties and neuroprotective effects. However, few mechanisms can explain the role of AST in the treatment of neuropathic pain. In the present study, we examined its potential to eliminate spinal nerve ligation (SNL) damage by inhibiting the phosphorylation of extracellular signal-regulated kinase (ERK)1/2, phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK), nuclear factor-kappa B (NF-kappa B) p65 and the inflammatory response. The results of behavior tests indicated the promising role of AST in analgesic effect in SNL mice. AST decreased the neuronal and non-neuronal activation, the levels of the inflammatory signaling mediators (p-ERK1/2 p-p38 MAPK and NF-kappa B p65) and inflammatory cytokine expression (interleukin [IL]-1, IL-17, IL-6, and tumor necrosis factor-alpha [TNF-alpha]. These results suggest that AST is a promising candidate to reduce nociceptive hypersensitization after SNL.

Automated summary

Neuropathic pain is a complex condition that can last a lifetime and has a significant negative impact on quality of life. Astaxanthin, a natural marine compound, has shown promise in reducing spinal nerve ligation (SNL) damage by inhibiting inflammatory responses and signaling pathways, suggesting its potential as a candidate for pain management in neuropathic pain.